Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.

CONCLUSION: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
PMID: 25782408 [PubMed - as supplied by publisher]

Source: Current Vascular Pharmacology - March 16, 2015 Category: Drugs & Pharmacology Authors: Ntalas IV, Kalantzi KI, Tsoumani ME, Vakalis I, Vasilakopoulos V, Vardakis C, Vemmos K, Voukelatou M, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Dimoulis N, Draganigos A, Efthimiadis I, Thoma M, Kazakos E, Kipouridis N, Konstantinou S, Milionis H Tags: Curr Vasc Pharmacol Source Type: research